Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support services; Warehousing, including dedicated storage, shared warehouses, packing and value-added services, such as labeling and products assembly; Logistics systems, including software for logistics management; Passenger transportation, including transportation of personnel and students; Special services, including rental of bus and vans; Moving, including national and international moving services, and Advertising, including custom transportation services during marketing campaigns. The Company operates through a number of group companies.


PINL:GRPOF - Post by User

Post by Golddetectoron Jul 25, 2021 7:52pm
225 Views
Post# 33602520

Important short term value creating milestones

Important short term value creating milestones Below are the main evens for q3 and q4 as per presentation on may 2021: many ppl think reduvo sales in q4 is most important even but IMO QIXLEEF q3 update and ard003 are way more important. If QIXLEEF pass ph ii that drug itself will worth 500 millions us at least. With positive indicators in place I think we have low risk but I think investors are looking for a stronger confirmation to de-risk the investment. We are getting close. Gl longs 

Short-Term Value-Creating Milestones
QIXLEEF - PLENITUDE:
Q2: ACCELERATE PATIENT ENROLMENT
Q3: RECEIVE OPINION FROM EMA – MALTA COMPETENT AUTHORITY
QIXLEEF – REBORN1:
Q2: 1ST PATIENT IN
Q3: INTERIM ANALYSIS
Q3: RECEIVE OPINION FROM EMA – MALTA COMPETENT AUTHORITY Q1-22: END OF ENROLMENT
ARDS-003:
Q4: LAST HEALTHY VOLUNTEER Q1-22: LAST PATIENT IN
CAU M Z:
BRIDGE TO QIXLEEF
R ED U VO :
Q4:DIN EXPECTED
ENJOUCA :
MARKET LAUNCH DATES: CANADA Q4 2021, AUSTRALIA Q1 2022, GERMANY Q2 2022
<< Previous
Bullboard Posts
Next >>